Glaucoma therapy and ocular surface disease: Current literature and recommendations

Current Opinion in Ophthalmology

Volumn 24, Issue 2, 2013, Pages 136-143

  Anwar, Zane ^a,b   Wellik, Sarah R ^a,b   Galora, Anat ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Benzalkonium Chloride; Glaucoma; Ocular Surface Disease; Preservatives; Recommendations

Indexed keywords

BENZALKONIUM CHLORIDE; BRIMONIDINE; COSOPT PF; DORZOLAMIDE PLUS TIMOLOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LATANOPROST; POLIDRONIUM CHLORIDE; SOFZIA; TAFLUPROST; TIMOLOL; TRAVOPROST; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; ANTIMICROBIAL ACTIVITY; APOPTOSIS; AQUEOUS HUMOR FORMATION; CELL SURVIVAL; CELL VIABILITY; CLINICAL FEATURE; CROSS REACTION; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; EYE ALLERGY; FEASIBILITY STUDY; GLAUCOMA; HUMAN; HYPEROSMOLARITY; IN VITRO STUDY; KERATOCONJUNCTIVITIS; MEIBOMIAN GLAND; MUCOUS MEMBRANE PEMPHIGOID; NEUROPATHY; NEUROTOXICITY; NONHUMAN; OCULAR SURFACE DISEASE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PUNCTATE KERATITIS; QUALITY OF LIFE; REVIEW; TEAR FILM;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZALKONIUM COMPOUNDS; CONJUNCTIVAL DISEASES; CORNEAL DISEASES; DRY EYE SYNDROMES; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; PRACTICE GUIDELINES AS TOPIC; PRESERVATIVES, PHARMACEUTICAL;

EID: 84876210030     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32835c8aba     Document Type: Review

References (60)

1. Varma R, Lee PP, Goldberg I, Kotak S. An assessment of the health and economic burdens of glaucoma. Am J Ophthalmol 2011; 152:515-522.
2. Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007; 144:533-540.
3. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008; 17:350-355.
4. Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol 2012; 153:1-9. Assessed the quality of life in patients with OSD and glaucoma. This study was able to demonstrate a poorer quality of life in glaucoma patients with OSD with statistical significance. Furthermore, predictors of OSD in these patients were identified.
5. Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressurelowering medications. Cornea 2010; 29:618-621.
6. Servat JJ, Bernardino CR. Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue. Drugs Aging 2011; 28:267-282.
7. Johnson DH, Kenyon KR, Epstein DL, Van Buskirk EM. Corneal changes during pilocarpine gel therapy. Am J Ophthalmol 1986; 101:13-15.
8. Maas S, Ros FE, De Heer LJ, De Keizer RJ. Long-term treatment with Pilogel/beta-blocker in glaucoma patients. Int Ophthalmol 1991; 15:281-284.
9. Aihara M, Otani S, Kozaki J, et al. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost. J Glaucoma 2012; 21:60-64. This crossover study evaluated SPK in patients who were transitioned to preservative-free therapy who were followed up to 12 months.
10. Inoue K, Okugawa K, Kato S, et al. Ocular factors relevant to antiglaucomatous eyedrop-related keratoepitheliopathy. J Glaucoma 2003; 12:480-485.
11. Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007; 17:341-349.
12. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002; 86:418-423.
13. Arici MK, Arici DS, Topalkara A, Guler C. Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin Experiment Ophthalmol 2000; 28:113-117.
14. Arita R, Itoh K, Maeda S, et al. Effects of long-term topical antiglaucoma medications on meibomian glands. Graefes Arch Clin Exp Ophthalmol 2012; 250:1181-1185. This study assessed abnormal meibomian gland function and morphology in addition to tear-film abnormalities in patients on long-term glaucoma therapy.
15. Arita R, Itoh K, Maeda S, et al. Comparison of the long-term effects of various topical antiglaucoma medications on meibomian glands. Cornea 2012; 31:1229-1234.
16. Herreras JM, Pastor JC, Calonge M, Asensio VM. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology 1992; 99:1082-1088.
17. Terai N, Muller-Holz M, Spoerl E, Pillunat LE. Short-term effect of topical antiglaucoma medication on tear-film stability, tear secretion, and corneal sensitivity in healthy subjects. Clin Ophthalmol 2011; 5:517-525.
18. Januleviciene I, Derkac I, Grybauskiene L, et al. Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma. Clin Ophthalmol 2012; 6:103-109. This crossover study measured tear-film parameters in patients transitioned to preservative-free therapy. Hyperosmolarity, which is difficult to monitor clinically, was notably included in this study.
19. Definition and Classification Subcommittee of the International Dry Eye Work Shop. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Work Shop (2007). Ocul Surf 2007; 5:75-92.
20. Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol 2005; 5:459-463.
21. Baudouin C, Labbe A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010; 29:312-334.
22. Hong J, Bielory L. Allergy to ophthalmic preservatives. Curr Opin Allergy Clin Immunol 2009; 9:447-453.
23. Mantelli F, Tranchina L, Lambiase A, Bonini S. Ocular surface damage by ophthalmic compounds. Curr Opin Allergy Clin Immunol 2011; 11:464-470.
24. Jappe U, Uter W, Menezes de Padua CA, et al. Allergic contact dermatitis due to beta-blockers in eye drops: a retrospective analysis of multicentre surveillance data 1993-2004. Acta Derm Venereol 2006; 86:509-514.
25. Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily:1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol 1999; 127:20-26.
26. Schuman JS, Horwitz B, Choplin NT, et al. A1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol 1997; 115:847-852.
27. Thorne JE, Anhalt GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology 2004; 111:45-52.
28. Kroll DM, Schuman JS. Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma. Am J Ophthalmol 2002; 133:401-403.
29. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol 1999; 127:602-604.
30. Domingo Gordo B, Urcelay Segura JL, Conejero Arroyo J, et al. Corneal decompensation in patients with endothelial compromise treated with topical dorzolamide. Arch Soc Esp Oftalmol 2002; 77:139-144.
31. Konowal A, Morrison JC, Brown SV, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol 1999; 127: 403-406.
32. Tressler CS, Beatty R, Lemp MA. Preservative use in topical glaucoma medications. Ocul Surf 2011; 9:140-158.
33. Paimela T, Ryhanen T, Kauppinen A, et al. The preservative polyquaternium-1 increases cytoxicity and NF-kappaB linked inflammation in human corneal epithelial cells. Mol Vis 2012; 18:1189-1196.
34. Clouzeau C, Godefroy D, Riancho L, et al. Hyperosmolarity potentiates toxic effects of benzalkonium chloride on conjunctival epithelial cells in vitro. Mol Vis 2012; 18:851-863. This in-vitro study demonstrated the importance of hyperosmolarity in corneal and conjunctival toxicity.
35. Pellinen P, Huhtala A, Tolonen A, et al. The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo. Curr Eye Res 2012; 37:145-154.
36. Ye J, Wu H, Zhang H, et al. Role of benzalkonium chloride in DNA strand breaks in human corneal epithelial cells. Graefes Arch Clin Exp Ophthalmol 2011; 249:1681-1687. This study provided one molecular mechanism to benzalkonium chloride toxicity by evaluating single-and double-stranded DNA breaks from exposure.
37. Ammar DA, Kahook MY. Effects of glaucoma medications and preservatives on cultured human trabecular meshwork and nonpigmented ciliary epithelial cell lines. Br J Ophthalmol 2011; 95:1466-1469.
38. Ammar DA, Kahook MY. Effects of benzalkonium chloride-or polyquadpreserved fixed combination glaucoma medications on human trabecular meshwork cells. Mol Vis 2011; 17:1806-1813.
39. Liang H, Pauly A, Riancho L, et al. Toxicological evaluation of preservativecontaining and preservative-free topical prostaglandin analogues on a threedimensional-reconstituted corneal epithelium system. Br J Ophthalmol 2011; 95:869-875.
40. Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells. Adv Ther 2011; 28:501-510. This in-vitro study compared multiple preservative (benzalkonium chloride, Polyquad, and SofZia) toxicity in corneal and conjunctival epithelial cells.
41. Li C, Song Y, Luan S, et al. Research on the stability of a rabbit dry eye model induced by topical application of the preservative benzalkonium chloride. PLoS One 2012; 7:e33688. This in-vivo study simulated the additive and prolonged exposure of benzalkonium chloride and measured tear film and cell morphology abnormalities.
42. Sarkar J, Chaudhary S, Namavari A, et al. Corneal neurotoxicity due to topical benzalkonium chloride. Invest Ophthalmol Vis Sci 2012; 53:1792-1802. This animal study evaluated benzalkonium chloride corneal neurotoxicity and subsequent patterns of nerve fiber regrowth during recovery.
43. Uematsu M, Kumagami T, Shimoda K, et al. Polyoxyethylene hydrogenated castor oil modulates benzalkonium chloride toxicity: comparison of acute corneal barrier dysfunction induced by travoprost Z and travoprost. J Ocul Pharmacol Ther 2011; 27:437-444.
44. Kim JR, Oh TH, Kim HS. Effects of benzalkonium chloride on the ocular surface of the rabbit. Jpn J Ophthalmol 2011; 55:283-293.
45. Liang H, Brignole-Baudouin F, Pauly A, et al. Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study. Adv Ther 2011; 28:311-325.
46. Friedlaender MH, Breshears D, Amoozgar B, et al. The dilution of benzalkonium chloride (BAK) in the tear film. Adv Ther 2006; 23:835-841.
47. Tonjum AM. Effects of benzalkonium chloride upon the corneal epithelium studied with scanning electron microscopy. Acta Ophthalmol (Copenh) 1975; 53:358-366.
48. Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloridepreserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther 2010; 27:837-845.
49. Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol 2011; 151:792-798; e791.
50. Martone G, Frezzotti P, Tosi GM, et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol 2009; 147:725-735; e721.
51. Ayaki M, Iwasawa A, Inoue Y. Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells. Clin Ophthalmol 2010; 4:1217-1222.
52. Stevens AM, Kestelyn PA, De Bacquer D, Kestelyn PG. Benzalkonium chloride induces anterior chamber inflammation in previously untreated patients with ocular hypertension as measured by flare meter: a randomized clinical trial. Acta Ophthalmol 2012; 90:e221-e224. This clinical study demonstrated a novel clinical manifestation of benzalkonium chloride. Inflammatory changes in the anterior chamber from benzalkonium chloride were compared with the fellow eye using a flare meter.
53. Gandolfi S, Paredes T, Goldberg I, et al. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma. Eur J Ophthalmol 2012; 22:34-44. This crossover clinical study is one of the more recent trials that did not find changes in OSD in patients after switching to benzalkonium chloride-free therapy.
54. Kitazawa Y, Smith P, Sasaki N, et al. Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. Eye (Lond) 2011; 25:1161-1169.
55. Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol 2010; 88:329-336.
56. Renieri G, Fuhrer K, Scheithe K, et al. Efficacy and tolerability of preservativefree eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients. J Ocul Pharmacol Ther 2010; 26:597-603.
57. Whitson JT, Trattler WB, Matossian C, et al. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2010; 26:287-292.
58. Katz G, Springs CL, Craven ER, Montecchi-Palmer M. Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAKpreserved latanoprost or BAK-free travoprost. Clin Ophthalmol 2010; 4:1253-1261.
59. Pouyeh B, Viteri E, Feuer W, et al. Impact of ocular surface symptoms on quality of life in a United States veterans affairs population. Am J Ophthalmol 2012; 153:1061-1066; e1063.
60. Rossi GC, Tinelli C, Pasinetti GM, et al. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol 2009; 19:572-579.